BRCA1 and neoplasm: Our observation of the benefit of capecitabine in patients with non-BRCA1-like tumours is in line with Alli et al. who found a 5-fold higher sensitivity to 5-fluorouracil of wild-type BRCA1 compared to BRCA1-deficient murine mammary epithelial cells [45].